ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2015
Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Whole-Body [Tomography (Ann Arbor, Mich.) · 2021Trial
- Does Measurement of First-Order and Heterogeneity Parameters Improve Response Assessment of Bone Metastases in Breast Cancer Compared to SUVMolecular imaging and biology · 2019Trial
- Quantitative Assessment of Early [Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017Trial
- Repeatability of Quantitative 18F-NaF PET: A Multicenter Study.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2016Trial
- Molecular image-directed biopsies: improving clinical biopsy selection in patients with multiple tumors.Physics in medicine and biology · 2016Trial
- Correlation of Positron Emission Tomography and Low-Field Standing Magnetic Resonance Imaging in Horses With Forelimb Lameness Localized to the Foot.Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association · 2026Article
- Theranostics Nuclear Medicine in Prostate Cancer.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Quantitative assessment ofAnnals of nuclear medicine · 2023Article
- Automated quantification of PET/CT skeletal tumor burden in prostate cancer using artificial intelligence: The PET index.European journal of nuclear medicine and molecular imaging · 2023Article
- A Retrospective Comparative Study of Sodium Fluoride NaLife (Basel, Switzerland) · 2022Article
- Current and future targeted alpha particle therapies for osteosarcoma: Radium-223, actinium-225, and thorium-227.Frontiers in medicine · 2022Review
- Combined bone scintigraphy and fluorocholine PET/computed tomography predicts response to radium-223 therapy in patients with prostate cancer.Future science OA · 2021Article
- Review
- A Retrospective Comparative Study of Sodium Fluoride (NaF-18)-PET/CT and Fluorocholine (F-18-CH) PET/CT in the Evaluation of Skeletal Metastases in Metastatic Prostate Cancer Using a Volumetric 3-D Radiomics Analysis.Diagnostics (Basel, Switzerland) · 2020Article
- Comparison ofEuropean journal of nuclear medicine and molecular imaging · 2020Article
- Evaluation of bone metastasis burden as an imaging biomarker by quantitative single-photon emission computed tomography/computed tomography for assessing prostate cancer with bone metastasis: a phantom and clinical study.Radiological physics and technology · 2020Article
- Normalization by bone volume instead of body weight or lean body mass may be better for quantifying skeletal burden in fibrous dysplasia using sodium fluoride PET/CT.European journal of nuclear medicine and molecular imaging · 2020Article
- Considerations on bone volume normalization in quantifying skeletal burden in fibrous dysplasia using sodium fluoride PET/CT.European journal of nuclear medicine and molecular imaging · 2020Article
- Quantifying skeletal burden in fibrous dysplasia using sodium fluoride PET/CT.European journal of nuclear medicine and molecular imaging · 2020Article
- Observer Agreement and Accuracy ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
Abstract
unlabelledThe purpose of this study was to define a method to assess skeletal tumor burden with 18F-labeled sodium fluoride PET/CT (18F-fluoride PET/CT) and evaluate the reproducibility of these measurements.
methodsNinety-eight consecutive patients (90 men; mean age±SD, 65.7±14.2 y) underwent 158 18F-fluoride PET/CT scans for evaluation of skeletal metastatic disease. In order to determine the mean normal bone SUV, initially a 1-cm spheric volume of interest (VOI) was placed over 5 bone sites: T12, L5, sacrum, right iliac bone, and right femur. For each patient, the mean SUVmax for all sites was generated. Afterward, a threshold value of normal bone uptake was established. Subsequently, skeletal tumor burden was determined by generating volumetric data using a whole-body segmentation method. Any SUVmax below the normal threshold was excluded from analysis, as were VOIs not related to metastatic disease. Statistics for the remaining VOIs were then generated and defined as the skeletal metastatic tumor burden by 2 parameters: total lesion fluoride uptake above an SUVmax of 10 (TLF10) and fluoride tumor volume above an SUVmax of 10 (FTV10). TLF10 and FTV10 reproducibility was determined using 2 independent and experienced PET/CT interpreters analyzing a subset of 13 18F-fluoride PET/CT scans.
resultsMean (±SD) normal bone SUVmax was 6.62±1.55 for T12, 6.11±1.73 for L5, 4.59±1.74 for sacrum, 5.39±1.72 for right iliac bone, and 3.90±1.57 for right femur. The mean normal SUVmax for all 543 sites was 5.32±0.99. On the basis of these values, an SUVmax threshold of 10 was chosen to exclude normal bone from the volumetric calculations. Semiautomated measurements of TLF10 and FTV10 exhibited high interobserver reproducibility, within ±0.77% and ±3.62% of the interinterpreter average for TLF10 and FTV10, respectively.
conclusionDetermination of skeletal tumor burden with 18F-fluoride PET/CT is feasible and highly reproducible. Using an SUVmax threshold of 10 excludes nearly all normal bone activity from volumetric calculations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.